Emgality (galcanezumab)

pCPA File Number: 21690
Negotiation Status:
Concluded with an LOI
Indication(s):
Prevention of migraine
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CDA-AMC Project Number:
SR0693
pCPA Engagement Letter Issued:
Negotiation Process Concluded: